Table 5.
Clinicopathological variables factors influenced response treatment of both groups of subjects
| Variable | Bivariate | Multivariate | ||
|---|---|---|---|---|
|
|
|
|||
| OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value | |
| Age (< 50 yr vs. ≥ 50 yr) | 1.400 (0.394–4.979) | 0.650 | - | - |
|
| ||||
| Menopause status (preM vs. postM) | 0.543 (0.144–2.049) | 0.364 | - | - |
|
| ||||
| BMI (≤ 25 vs. > 25) | 4.231 (0.837–21.397) | 0.100 | 3.559 (0.602–21.032) | 0.161 |
|
| ||||
| Staging (operable vs. inoperable) | 1.645 (0.392–6.904) | 0.743 | - | - |
|
| ||||
| LDL (normal vs. high) | 3.000 (0.442–20.371) | 0.243 | 5.433 (0.621–47.540) | 0.126 |
|
| ||||
| Cholesterol (high vs. normal) | 0.657 (0.183–2.363) | 0.519 | - | - |
|
| ||||
| Grade (low vs. high) | 1.000 (0.282–3.544) | > 0.99 | - | - |
|
| ||||
| ER/PR status (positive vs. negative) | 0.306 (0.035–2.638) | 0.428 | - | - |
|
| ||||
| HER-2 (non-amplified vs. amplified) | 4.200 (1.121–15.731) | 0.026 | 2.753 (0.605–12.524) | 0.190 |
|
| ||||
| TNBC (yes vs. not) | 1.286 (1.115–1.483) | 0.333 | - | - |
|
| ||||
| Ki-67 (< 14% vs. ≥ 14%) | 3.270 (0.379–28.214) | 0.428 | - | - |
|
| ||||
| TOP II alpha (> 15% vs. ≤ 15%) | 0.510 (0.141–1.841) | 0.299 | - | - |
|
| ||||
| NACT (Plb+FAC vs. Simv+FAC) | 3.857 (0.927–16.048) | 0.053 | 3.826 (0.770–19.022) | 0.101 |
BMI, body mass index; CI, confidence interval; ER, estrogen receptor; FAC, fluorouracil, adriamycin, and cyclophosphamide; HER2, human epidermal growth factor receptor 2; LDL, low-density lipoprotein; NACT, neo-adjuvant chemotherapy; OR, odds ratio; Plb, placebo; PR, progesterone receptor; Simv, simvastatin; TNBC, triple-negative breast carcinoma.